Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
Clinical Case Reports
Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.
Limaye, Sewanti; Patil, Darshana; Akolkar, Dadasaheb; and Srivastava, Navin, "Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma" (2021). Open Access archive. 2359.